Twenty-Seven Dead, No FDA Approval, and a Presidential Pen

At least twenty-seven Americans have died taking ibogaine at unregulated clinics abroad, and the drug still has no FDA approval. President Donald Trump signed an executive order on April 18, 2026 directing the FDA to speed up its review anyway, holding the signed document in the Oval Office that afternoon. ²⁸

The number that matters first is the death toll. It comes from Dr. Céline Gounder, the CBS News contributor and infectious-disease physician who has tracked ibogaine's off-label use for years. Gounder reported that Americans have died at foreign clinics while the formal evidence base for the drug remains thin. ⁸ That figure — twenty-seven — is the cleanest count of fatalities attached to specific American names. The wider toll, including deaths at clinics that do not track nationality, is not in the public record.

Ibogaine is a psychoactive compound derived from the root bark of the Tabernanthe iboga shrub, used traditionally in Central and West Africa. In the United States it sits on the DEA's Schedule I list of controlled substances, the same category as heroin, defined as having no accepted medical use and a high potential for abuse. ³⁹ No psychedelic compound of any kind is currently FDA-approved. ⁷ The April order did not reclassify ibogaine or approve it. It told the FDA to move faster. ⁹

The central safety concern with ibogaine is the heart. Experts warn that ibogaine can prolong the heart's QT interval — the electrical pause between beats — which can trigger arrhythmias and sudden cardiac death, particularly in patients with pre-existing risk factors or those who relapse and take the drug again. ¹¹ Model Diplomat's summary is blunt: there is no completed U.S. trial and a well-documented cardiac risk. ⁹

The strongest published evidence in ibogaine's favor is a 2024 Stanford-led open-label trial of magnesium-ibogaine treatment, which reported large short-term reductions in PTSD, depression and anxiety symptoms. ¹¹ The study was small and not randomized — meaning patients knew what they were getting and there was no control group — which limits what regulators can draw from it. Gounder's argument is that federal money is now arriving ahead of the evidence base that would justify it. ⁸

Texas has committed tens of millions of dollars to ibogaine research. ⁷ The April order added federal matching funds, a flow of public money into a treatment that American veterans and conservative lawmakers have embraced despite the safety warnings. ²¹⁰ Texans with PTSD and opioid addiction have been crossing the border into Mexico for ibogaine, which is not legal in the U.S. ⁶

That pipeline — patients leaving the country, money following them back as research grants — is the political shape of the issue. Combat veterans and their advocates have become a vocal constituency, and the executive order is in part a response to that pressure. The White House had been drafting the order as early as April 16, according to CBS reporting by Jennifer Jacobs and Dr. Céline Gounder. ⁵

The drug sits inside a regulatory contradiction. It is illegal to possess in the United States without research authorization, but American patients travel to clinics in Mexico and elsewhere to take it under medical supervision. Those clinics operate under foreign medical regulations, not U.S. ones, and the U.S. Food and Drug Administration has no jurisdiction over how they administer the drug. When Americans die abroad, no U.S. agency tracks the cases systematically. ⁸

The order's mechanism is procedural rather than scientific. It directs the FDA to expedite ibogaine's review; it does not unlock the drug for prescription use. ⁹ Anyone reading the executive order as immediate access is reading it wrong. What it does is change the timetable, not the rules.

The political momentum behind ibogaine is real. Veterans' groups, conservative donors, and the President's signature are all pulling in the same direction. The clinical evidence is moving more slowly. A small, unrandomized Stanford trial is the most recent published data point; QT prolongation is the most consistent safety signal. Between the two sits the executive order, which compresses the timeline without resolving the disagreement.

The April order changed the politics of ibogaine. It did not change the pharmacology. The drug's QT-prolonging effect is a property of the molecule, not of the executive order. Until randomized U.S. trials report results — and no such trial has completed — the gap between the promise and the proof is the story.